A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
NPS MedicineWise media release – bDMARDS September 2019 (002)
Discover more...
-
Arthritis and musculoskeletal conditions affect 7 million Australians
Click here to email your MP today 7 million voices | 7 million stories Arthritis and musculoskeletal conditions affect almost 1 in 3 Australians One...
-
Arthritis Australia | 2024 year in review
In 2024, Arthritis Australia made significant strides in advocating for better care for the 7+ million Australians living with arthritis and musculoskeletal conditions. Parliamentary Summit...
-
National Research Program information session for researchers
We are committed to improving the lives of Australians living with arthritis and musculoskeletal conditions through impactful, relevant research. We’re excited to announce our new...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
